CrossrefInfokarte
Phase 2 Trial of 89 Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma
Radiology · 2026-11-01 · 321 (2)
DOI: 10.1148/radiol.260517 ↗Abstract
In participants with multiple myeloma, CD38-targeted zirconium 89 deferoxamine-daratumumab immuno-PET/CT helped detect active myeloma, even in some participants with no signs of disease at fluorine 18 fluorodeoxyglucose PET/CT.
EUVIMED